Underweight LMT: Trim 20-25% to 75-80% Weight, Hedge Residual, Redeploy to Short-Duration Treasuries
This is a TIMING call against an intact QUALITY franchise. The structural thesis ($160B+ backlog, sole-source oligopoly on PAC-3/F-35/THAAD/Trident, beta 0.10, 13-year dividend growth streak, Iran conflict demand) remains intact and prohibits magnitude-overshoot to full Sell. The 10/06 binding reflection mandates the upper bound of the trim range (20-25%); the 10/02 binding reflection mandates preservation of meaningful residual (75-80%) to honor the structural floor. The Neutral Analyst's portfolio-level architecture — trim + put spread hedge + redeploy to short-duration Treasuries — is the cleanest synthesis. Price target $485.00.
| Position | Action |
|---|---|
| Current levels (~$506) | Trim 20-25% of LMT position to reach 75-80% of benchmark weight |
| Post-trim residual position | Buy $500/$480 put spread for November cycle (~1.5-2% of residual notional) |
| Close below $490 on expanding volume ≥3.5M shares | Full exit residual — structural invalidation confirmed |
| $540 reclaim with volume ≥1.2M, RSI >40, and MACD histogram turning positive | Re-engage residual position |
| Q3 2026 earnings: operating margin ≥12.0%, FCF ≥$1.5B, buyback resumption authorized | Re-engage residual position |
LMT presents an asymmetric setup where macro headwinds are already priced in (stock off 27% from highs, P/E below historical average) while active-conflict demand for defense systems and Q2 2026 margin recovery are not yet reflected in the valuation.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 514.26 | bearish |
| close_50_sma | 552.77 | bearish |
| close_200_sma | 557.13 | bearish |
| macd | -11.43 | bearish |
| macd_signal | -10.20 | bearish |
| macdh | -1.23 | neutral |
| rsi | 32.37 | neutral |
| boll | 523.46 | neutral |
| boll_ub | 545.44 | bearish |
| boll_lb | 501.49 | bullish |
| vwma | ~522.25 | bearish |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Q3 2026 operating margin ≥12.0% AND FCF ≥$1.5B AND buyback resumption authorization (8-K filing)
Then: Upgrade to Hold and re-engage residual position
Q2 2026 margin recovery is real and structural, not transient
↩ rebuts: “Bear argument that 2024-2025 margin pressure is a structural problem”
EV: +3.3% to +9% · concedes: Narrow market leadership is currently favoring tech over industrials; Price is below all three moving averages (10 EMA 514, 50 SMA 553, 200 SMA 557); Death cross technical alignment exists; Highest yields since 2002 is a genuine macro headwind; This is not a momentum trade
LMT is a high-quality company but a poor investment at current levels; the "patient capital" thesis is a trap as the entry point offers no margin of safety given flat-to-down fundamentals, a confirmed technical downtrend, and a macro regime that could further compress valuations.
→ vs conservative: Anchoring to past regime, worshipping defense-sector reflexes, and confusing low beta with downside protection is wrong; in a regime change with 4.5% ten-year yields, long-duration equities get crushed regardless of geopolitical premium
→ vs neutral: Stop at 553 above the 50 SMA and 50% allocation cap constitutes a hedge, not a position; if the macro setup is the most hostile for long-duration equities in two decades and the technicals confirm a multi-month downtrend, leaving convexity on the table is misallocated risk
| atr | 11.23 | neutral |
Support: 501.49 · 497 | Resistance: 514.26 · 523.46 · 533 · 552.77 · 557.13
LMT exhibits a confirmed downtrend across all timeframes: price (506.63 verified close as of 2026-10-05) is below the 10 EMA (514.26), 50 SMA (552.77), and 200 SMA (557.13), with the 10 EMA in bearish alignment below both longer averages. Momentum indicators show RSI at 32.37 near oversold territory while the MACD histogram (-1.23) suggests decelerating bearish momentum, creating a setup for potential mean-reversion toward the Bollinger middle band at 523.46 (~3.3% upside). The recommendation is HOLD with a tactical short-bias; new longs require price to reclaim the 10 EMA at 514.26, while a confirmed close below the lower Bollinger band (501.49) would invalidate the oversold-bounce thesis. Data discrepancy noted: CSV shows 2026-10-07 close at 499.22 vs. verified snapshot 506.63.
Market Cap
$115.2B
PE Ratio (TTM)
18.40
Forward PE
15.27
PEG Ratio
0.96
Price/Book
13.10
Dividend Yield
2.71%
52-Week High
$692.00
52-Week Low
$437.25
50-Day MA
$553.23
200-Day MA
$563.21
Beta
0.095
Revenue (TTM)
$77.01B
Gross Profit (TTM)
$9.09B
EBITDA (TTM)
$9.68B
Net Income (TTM)
$6.29B
Operating Margin
11.96%
Profit Margin
8.16%
Gross Margin (TTM)
~11.8%
EBITDA Margin (TTM)
~12.6%
FCF Margin
~7.2%
Return on Equity (TTM)
89.17%
Return on Assets (TTM)
8.64%
EPS (TTM)
$27.13
Forward EPS
$32.69
Diluted EPS (FY 2025)
$21.49
Diluted EPS (FY 2024)
$22.31
Diluted EPS (FY 2023)
$27.55
Diluted EPS (FY 2022)
$21.66
Total Assets
$62.45B
Total Debt
$20.54B
Net Debt
$16.75B
Stockholders Equity
$8.77B
Tangible Book Value
($4.32B)
Current Ratio
1.19
Debt/Equity
234.2%
Working Capital
$4.59B
Net Debt / EBITDA
~1.7x
Pension Obligations
$3.93B
Free Cash Flow (TTM)
$5.56B
Q2'26 Operating CF
$3.24B
Q2'26 FCF
$2.92B
LTM Dividends Paid
~$3.17B
Q2'26 Revenue
$20.06B
Q2'26 Net Income
$1.84B
Q2'26 EPS
$7.94
Q2'26 Operating Margin
12.4%
Q2'25 EPS
$1.46
Total Revenue (FY 2025)
$75.05B
Total Revenue (FY 2024)
$71.04B
Total Revenue (FY 2023)
$67.57B
Total Revenue (FY 2022)
$65.98B
Net Income (FY 2025)
$5.02B
Net Income (FY 2023)
$6.92B
Net Income (FY 2022)
$5.73B
Effective Tax Rate (FY 2025)
15.3%
Goodwill
$11.30B
Receivables
$19.39B
Strengths
Concerns
Lockheed Martin presents as a quality defensive holding with reasonable valuation at a forward P/E of 15.27x and an attractive 2.71% dividend yield, though near-term momentum is limited as the stock consolidates near its 200-day moving average. Q2 2026 results showed strong margin recovery to 12.4% operating margin with EPS of $7.94 (5x the depressed Q2 2025), supporting the analyst consensus for a ~20% earnings rebound to $32.69 forward EPS. Key risks include fixed-price contract execution challenges causing 2024-2025 margin compression, F-35 program concentration, and government budget sensitivity, while structural positives include very low beta (0.095), robust $5.56B TTM free cash flow, and the company's investment-grade balance sheet with improving working capital position.
Macro: The macro environment is characterized by a rare split signal: defense demand is structurally strong due to an active Iran conflict driving inflation, while the Fed policy backdrop is the most hawkish in over two decades with 96% no-cut probability and 10Y yields at highest since 2002. This creates a \"no-landing-lite\" regime where growth persists (6% recession probability) but rates remain restrictive, pummeling long-duration equities and narrow tech-led equity leadership at records. Bitcoin fell below $83,000 suggesting risk-off in speculative assets but not yet broad contagion. Polymarket liquidity on the no-cut scenario stands at $8.8M, providing the deepest signal on rate expectations.